Cargando…
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Autores principales: | Xie, Yuanchao, Yin, Wanchao, Zhang, Yumin, Shang, Weijuan, Wang, Zhen, Luan, Xiaodong, Tian, Guanghui, Aisa, Haji A., Xu, Yechun, Xiao, Gengfu, Li, Jia, Jiang, Hualiang, Zhang, Shuyang, Zhang, Leike, Xu, H. Eric, Shen, Jingshan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477624/ https://www.ncbi.nlm.nih.gov/pubmed/34584244 http://dx.doi.org/10.1038/s41422-021-00570-1 |
Ejemplares similares
-
Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model
por: Zhang, Ruxue, et al.
Publicado: (2022) -
A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir
por: Zhang, Yumin, et al.
Publicado: (2023) -
Practical and Highly
Efficient Synthesis of Remdesivir
from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022) -
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
por: Yin, Wanchao, et al.
Publicado: (2020) -
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
por: Su, Haixia, et al.
Publicado: (2021)